Abstract: Provided herein are compositions and methods directed toward the discovery of improved methods for generating deoxyATP (dATP) in cells that can be delivered to a graft site in the heart to enhance cardiac function.

Abstract: Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.

Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in cardiac cell therapies. In some embodiments, the one or more modifications attenuate or prevent engraftment arrhythmia associated with a cardiac cell therapy.

Abstract: Described herein are compositions and methods related to enhancing cardiomyocyte transplant engraftment and methods of administering a transplant composition.

Abstract: Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.

Abstract: Provided herein are methods that enable the polarization of hPSC mesoderm such that closely related yet distinct cardiovascular populations can be generated efficiently without the need of post-facto enrichment.

Abstract: Described herein are compositions and methods related to the treatment of a cardiovascular disease or disorder. Also described herein are cells, stem cells (including embryonic and pluripotent stem cells), and in vitro-differentiated human cardiomyocytes in which HCN4 (HCN4), Cav3.2 (CACNA1H) and NCX1 (SLC8A1) activities are at least partially inhibited, and Kir2.1 (KCNJ2) activity is at least partially stimulated in such cells. Also described herein are formulations for the delivery of such cells and methods of transplanting cardiomyocytes, e.g., for the treatment or prevention of a disease or disorder.

Abstract: Described herein are compositions and methods relating to the improvement of cardiac function. Various embodiments relate to transplant compositions comprising cardiomyocytes which are engineered to be non-contractile, and to methods of using such cardiomyocytes or transplant compositions to improve cardiac function, e.g., by administering them to cardiac tissue.

Abstract: The present disclosure provides for the treatment of cardiac diseases and disorders using in vitro-differentiated cardiomyocytes. Such methods can take advantage of both autologous and allogeneic pluripotent stem cells.

Abstract: Disclosed herein are hypoimmunogenic cells for administering to a sensitized patient. In some instances, the patient is sensitized from a previous pregnancy or a previous transplant. In some embodiments, the cells exogenously express CD47 proteins and exhibit reduced expression of MHC class I proteins, MHC class II proteins, or both.

Abstract: Provided herein are methods and compositions comprising cardiomyocytes and epicardial cells for the treatment of cardiac disease.

Abstract: Described herein are methods and compositions for reducing or preventing arrhythmias associated with or caused by transplantation of cardiomyocytes to cardiac tissue. In particular embodiments, the pre-treatment of in vitro-differentiated cardiomyocytes with amiodarone before administration to cardiac tissue for engraftment reduces or prevents engraftment arrhythmias, and/or reduces the need for adjunctive anti-arrhythmia drugs after cell administration.

Abstract: Described herein are methods and compositions related to treating and preventing an engraftment arrhythmia with an effective amount of amiodarone and ivabradine. Also described herein is a method of cardiomyocyte transplant, the method comprises: dministering in vitro-differentiated cardiomyocytes to cardiac tissue of a subject in need thereof; and administering to the subject an amount of amiodarone and an amount of ivabradine effective to reduce engraftment arrhythmia in the subject.

Abstract: Provided are methods and uses related to cardiomyocyte cell therapies involving the administration of immunosuppressive agents for reducing or preventing rejection of administered allogeneic cardiomyocytes. In some embodiments, the methods are for treating a subject with a heart disease or condition in combination with a cardiomyocyte cell therapy.

Abstract: Described herein are methods and compositions related to methods of improving survival and engraftment of human cells differentiated in vitro, and uses thereof.

Abstract: Described herein are methods and compositions related to promoting maturation of in vitro-differentiated cardiomyocytes and in vitro-differentiated neurons, and methods and compositions using the resulting cardiomyocytes and neurons.

Abstract: Devices and techniques for magnetic detection of myocardial forces are generally described. In some examples, cardiac tissue may be cultured such that the cardiac tissue adheres to a first post and a second post. In further examples, a magnetometer may detect a change in a magnetic field resulting from a deflection of the first post in a first direction from a first position to a second position. In some other examples a signal corresponding to the change in the magnetic field may be generated. In still other examples, frequencies of the signal outside of a first frequency range may be excluded to produce a filtered signal. In various examples, the first frequency range may include frequencies associated with beating of cardiac tissue. In still further examples, a force exerted by the cardiac tissue may be determined based at least in part on the filtered signal.

Abstract: Disclosed herein are hypoimmunogenic cells for administering to a sensitized patient. In some instances, the patient is sensitized from a previous pregnancy or a previous transplant. In some embodiments, the cells exogenously express CD47 proteins and exhibit reduced expression of MHC class I proteins, MHC class II proteins, or both.

Abstract: Provided herein are methods that enable the polarization of hPSC mesoderm such that closely related yet distinct cardiovascular populations can be generated efficiently without the need of post-facto enrichment.

Abstract: Provided herein are methods that enable the polarization of hPSC mesoderm such that closely related yet distinct cardiovascular populations can be generated efficiently without the need of post-facto enrichment.